Chinese Academy of Medical Sciences

Phase 2 SENTRY trial data showed selinexor plus ruxolitinib effective and safe for MF patients previously treated with ruxolitinib, with 88% reduction in spleen length and 36% spleen response. Phase 3 trial now enrolls MF patients naive to JAK inhibitors.

Selinexor plus ruxolitinib was safe and effective in reducing spleen length and symptoms in myelofibrosis patients previously treated with ruxolitinib, with 88% showing spleen reduction and 86.67% experiencing symptom alleviation, according to the phase 2 SENTRY trial.

A phase II trial of radiation, chemotherapy, and immunotherapy in unresectable locally advanced esophageal squamous cell carcinoma showed tumor shrinkage, enabling surgery in 66.7% of patients, and improved survival rates (1-year PFS: 79.4%, OS: 89.6%).

Combination of radiation, chemotherapy, and immunotherapy in esophageal cancer patients made tumors more amenable to surgery, significantly improving survival outcomes, according to a phase II clinical trial published in Clinical Cancer Research.

Combining radiation, chemotherapy, and immunotherapy can shrink advanced esophageal cancer tumors, enabling surgery with better survival rates. A clinical trial showed that over half of patients who underwent surgery were disease-free two years later, significantly outperforming non-surgical treatment alone.

IASO Bio's Equecabtagene Autoleucel (Fucaso™) showed high efficacy and safety in treating relapsed/refractory multiple myeloma, with a 96% overall response rate and 74.3% stringent complete response/complete response rate, published in JAMA Oncology.

Synthetic lethality, exemplified by PARP1, WRN, and PRMT5, drives anticancer drug development, enhancing efficacy and safety. This strategy identifies gene pairs for targeted tumor treatment, minimizing normal cell impact.

Huan Xi and colleagues advocate for tailored strategies to integrate frailty assessment into multimorbidity management, promoting a shift towards health-oriented care. They highlight the importance of frailty assessment as a breakthrough point for managing multimorbidity, emphasizing its predictive power for clinical outcomes and quality of life. Despite global advancements in guidelines, tools, and strategies, real-world implementation in China faces challenges such as lack of localized guidelines and physician incentives. The authors suggest leveraging community-based initiatives and digital health technologies to enhance frailty assessment and multimorbidity management, advocating for a shift from disease-centered to health-centered care.

Darolutamide plus androgen-deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) by 46% versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups and a favorable safety profile.

HS-20093, a B7-H3–targeted ADC, showed promising efficacy in ES-SCLC patients with ORR of 61.3% at 8 mg/kg and 50.0% at 10 mg/kg in the ARTEMIS-001 trial. The 8 mg/kg dose had a better safety profile with no new safety signals identified. B7-H3 expression had a low correlation with tumor response.